Rhythm Pharmaceuticals(RYTM)
$112.16-1.79 (-1.57%)
RYTM
Rhythm Pharmaceuticals financials statements
$112.16
At close:-1.79 (-1.57%)
Want to see RYTM full AI Analyst Report?
Rhythm Pharmaceuticals (RYTM) Ratios
626 Followers
Rhythm Pharmaceuticals Ratios
RYTM's free cash flow for Q3 2026 was $-3.56M. For the 2026 fiscal year, RYTM's free cash flow was decreased by $-500.00K and operating cash flow was $-3.06M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.41 | 3.24 | 5.58 | 8.90 | 7.10 |
| Quick Ratio | 4.16 | 3.08 | 5.43 | 8.83 | 7.10 |
| Cash Ratio | 0.51 | 0.77 | 1.09 | 3.21 | 1.36 |
| Solvency Ratio | -0.93 | -1.14 | -1.12 | -1.52 | -1.51 |
| Operating Cash Flow Ratio | -1.09 | -0.99 | -2.47 | -4.36 | -3.36 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 256.75M | $ 146.48M | $ 145.28M | $ 236.02M | $ 263.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.78 | 2.38 | 1.96 | 1.45 | 1.16 |
| Debt Service Coverage Ratio | -8.48 | -11.57 | -12.17 | -33.50 | 0.00 |
| Interest Coverage Ratio | -9.33 | -12.89 | -13.27 | -34.45 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.38 | 0.40 | 0.26 | 0.14 | 0.05 |
| Net Debt to EBITDA | 0.29 | 0.36 | 0.35 | 0.72 | 0.83 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% |
| EBIT Margin | -92.47% | -184.17% | -219.85% | -744.22% | -2207.10% |
| EBITDA Margin | -91.76% | -182.97% | -217.58% | -737.14% | -2170.39% |
| Operating Profit Margin | -101.19% | -204.04% | -238.10% | -757.92% | -5391.85% |
| Pretax Profit Margin | -103.31% | -200.00% | -237.79% | -766.22% | -2207.10% |
| Net Profit Margin | -103.57% | -200.27% | -238.52% | -766.22% | -2207.10% |
| Continuous Operations Profit Margin | -103.57% | -200.27% | -238.52% | -766.22% | -2207.10% |
| Net Income Per EBT | 100.25% | 100.13% | 100.31% | 100.00% | 100.00% |
| EBT Per EBIT | 102.10% | 98.02% | 99.87% | 101.10% | 40.93% |
| Return on Assets (ROA) | -40.93% | -66.43% | -55.50% | -47.35% | -21.13% |
| Return on Equity (ROE) | -72.79% | -158.37% | -108.79% | -68.54% | -24.50% |
| Return on Capital Employed (ROCE) | -51.31% | -95.93% | -66.42% | -52.28% | -59.44% |
| Return on Invested Capital (ROIC) | -51.22% | -95.93% | -66.24% | -52.18% | -59.32% |
| Return on Tangible Assets | -41.39% | -67.50% | -56.70% | -48.35% | -21.43% |
| Earnings Yield | -2.83% | -7.63% | -6.97% | -11.93% | -14.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.28 | 7.03 | 5.21 | 3.80 | 3.08 |
| Payables Turnover | 1.40 | 1.08 | 1.90 | 0.44 | 0.10 |
| Inventory Turnover | 0.76 | 0.71 | 1.08 | 0.73 | 5.40 |
| Fixed Asset Turnover | 45.69 | 31.67 | 36.49 | 7.00 | 0.73 |
| Asset Turnover | 0.40 | 0.33 | 0.23 | 0.06 | 0.01 |
| Working Capital Turnover Ratio | 0.61 | 0.51 | 0.27 | 0.08 | 0.01 |
| Cash Conversion Cycle | 271.24 | 227.03 | 216.80 | -225.60 | -3309.58 |
| Days of Sales Outstanding | 50.17 | 51.93 | 70.08 | 96.11 | 118.62 |
| Days of Inventory Outstanding | 482.24 | 511.70 | 338.40 | 499.16 | 67.64 |
| Days of Payables Outstanding | 261.17 | 336.60 | 191.68 | 820.86 | 3495.83 |
| Operating Cycle | 532.41 | 563.63 | 408.48 | 595.26 | 186.26 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.78 | -1.87 | -2.36 | -3.33 | -2.94 |
| Free Cash Flow Per Share | -1.79 | -1.87 | -2.36 | -3.41 | -3.05 |
| Dividend Paid and CapEx Coverage Ratio | -121.38 | -28.68 | -2896.96 | -40.51 | -26.87 |
| Capital Expenditure Coverage Ratio | -121.38 | 0.00 | -2896.96 | -40.51 | -26.87 |
| Operating Cash Flow Coverage Ratio | -28.98 | -28.92 | -108.06 | -89.21 | -57.23 |
| Operating Cash Flow to Sales Ratio | -0.61 | -0.88 | -1.76 | -7.34 | -46.29 |
| Free Cash Flow Yield | -1.68% | -3.34% | -5.14% | -11.71% | -30.59% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -34.42 | -12.90 | -14.36 | -8.38 | -7.11 |
| Price-to-Sales (P/S) Ratio | 36.66 | 26.24 | 34.24 | 64.21 | 156.95 |
| Price-to-Book (P/B) Ratio | 25.76 | 20.75 | 15.62 | 5.74 | 1.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -59.64 | -29.98 | -19.47 | -8.54 | -3.27 |
| Price-to-Operating Cash Flow Ratio | -60.13 | -29.98 | -19.47 | -8.75 | -3.39 |
| Price-to-Earnings Growth (PEG) Ratio | 1.21 | -0.36 | 1.63 | -0.05 | 0.13 |
| Enterprise Value Multiple | -39.66 | -13.98 | -15.39 | -7.99 | -6.40 |
| Enterprise Value | 6.91B | 3.33B | 2.59B | 1.39B | 438.31M |
| EV to EBITDA | -39.66 | -13.98 | -15.39 | -7.99 | -6.40 |
| EV to Sales | 36.39 | 25.59 | 33.48 | 58.89 | 138.97 |
| EV to Free Cash Flow | -59.21 | -29.24 | -19.03 | -7.83 | -2.89 |
| EV to Operating Cash Flow | -59.70 | -29.24 | -19.04 | -8.03 | -3.00 |
| Tangible Book Value Per Share | 4.07 | 2.60 | 2.82 | 4.92 | 5.63 |
| Shareholders’ Equity Per Share | 4.16 | 2.70 | 2.94 | 5.07 | 5.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.92 | 2.13 | 1.34 | 0.45 | 0.06 |
| Net Income Per Share | -3.02 | -4.27 | -3.20 | -3.47 | -1.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.12 | 1.09 | 1.08 | 1.03 | 1.00 |
| Research & Development to Revenue | 0.88 | 1.83 | 1.74 | 4.60 | 33.01 |
| SG&A to Revenue | 1.03 | 1.11 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.35 | 0.30 | 0.42 | 0.84 | 6.60 |
| Income Quality | 0.59 | 0.44 | 0.74 | 0.96 | 2.10 |
Currency in USD
